RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$3.35
+0.19 (+6.01%)
Open$3.28
Previous Close$3.16
Day High$3.38
Day Low$3.19
52W High$5.45
52W Low$2.40
Volume—
Avg Volume3.53M
Market Cap365.80M
P/E Ratio—
EPS$-1.88
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+403.6% upside
Current
$3.35
$3.35
Target
$16.87
$16.87
$13.87
$16.87 avg
$23.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |
| Rev Growth | +1.5% | +16.6% | +10.7% |
| Debt/Equity | 1.36 | 1.21 | 1.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |